Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain

Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief - Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 TEL AVIV, Is... Biopharmaceuticals, Orthopaedic, FDA Moebius Medical, knee osteoarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news